SRI, Spyglass to Commercialize Underwater Mass Spec Technology | GenomeWeb

NEW YORK (GenomeWeb News) – SRI International and Spyglass Technologies today announced an exclusive licensing deal to commercialize SRI's underwater mass spectrometry technology.

The agreement calls for St. Petersburg, Fla.-based Spyglass to apply SRI's in situ membrane introduction mass spec (MIMS) technology to "a broad range of commercial, research, and government applications." Additionally, Spyglass will bundle the MIMS device with other underwater sensors, and the partners will continue collaborating on applications of the technology for other markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: random DNA replication errors play role in cancer, and more.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.